Avidity Partners Management LP / NBIX
Avidity Partners Management LP’s Neurocrine Biosciences Inc Position
Does Avidity Partners Management LP own Neurocrine Biosciences Inc (NBIX)? Not currently — the last reported position was 85.7K shares worth $9M in Q1 2025; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$9M
Q1 2025
Shares
85.7K
% of Portfolio
+1.81%
Quarters Held
19
position exited
Position History NBIX
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2025 | 85.7K | $9M | +1.81% |
| Q4 2024 | 220.4K | $30M | +2.95% |
| Q3 2024 | 460.0K | $53M | +2.70% |
| Q2 2024 | 491.0K | $68M | +2.87% |
| Q1 2024 | 536.5K | $74M | +2.39% |
| Q4 2023 | 658.0K | $87M | +3.16% |
| Q3 2023 | 652.1K | $73M | +2.95% |
| Q2 2023 | 665.3K | $63M | +2.19% |
| Q1 2023 | 815.7K | $83M | +2.74% |
| Q4 2022 | 1.78M | $213M | +4.61% |
| Q3 2022 | 1.86M | $197M | +4.01% |
| Q2 2022 | 1.47M | $143M | +3.28% |
| Q1 2022 | 1.16M | $109M | +2.26% |
| Q4 2021 | 1.26M | $107M | +2.28% |
| Q3 2021 | 848.9K | $81M | +1.80% |
| Q2 2021 | 681.0K | $66M | +1.79% |
| Q1 2021 | 521.4K | $51M | +1.40% |
| Q4 2020 | 300.0K | $29M | +0.93% |
| Q2 2020 | 185.1K | $23M | +1.45% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Avidity Partners Management LP’s full portfolio or all institutional holders of NBIX.